BioCentury
ARTICLE | Company News

Short seller accuses GenScript of CAR T data fraud

September 27, 2018 11:55 PM UTC

GenScript Biotech Corp. (HKSE:1548) shed HK$4.34 (27%) to HK$11.86 before halting trading Thursday after a report published by short seller Flaming Research accused the company of manipulating data and concealing safety issues during clinical development of CAR T therapy LCAR-B38M (JNJ-68284528).

Flaming Research describes itself on its website as an organization founded by equity investors aimed at "exposing fraudulent companies to protect the interest of minority shareholders" on the Hong Kong stock exchange, although it also notes via a disclaimer that it holds short positions in the stocks covered in its reports...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article